- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Intratumoral Injection of LTX-315 in Combination with Pembrolizumab in Patients with Percutaneously Accessible Lesions with Advanced Melanoma Refractory to PD-1/PD-L1 Inhibitor Therapy
This study looks at a new treatment for advanced melanoma that has not responded to previous immunotherapy. It combines an injected drug (LTX-315) with an existing cancer drug (Pembrolizumab) to see if it can shrink tumours and extend life. Researchers will closely monitor participants' health.
For: Advanced MelanomaFrance · Norway · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable /Metastatic Solid Tumors Who are Refractory to Available Standard Therapies
This study is testing a new medicine called SKB264 for people with advanced solid tumours that haven't responded to other treatments. It's a first step to see how safe and effective SKB264 is, and to understand its effects on the body.
For: Metastatic or locally advanced unresectable solid tumors progressing after available standard therapiesSpain · Italy